Background: Blood microparticles (MPs) are phospholipid microvesicles derived from cell membranes. Typically, they range in size from 0.1 μm to 1.0 μm and they are released upon oxidative stress, cell activation, injury or apoptosis. MPs have acquired a biological and clinical interest and are recognized as entities able to modulate many biological functions. Literature suggests that they may have a role in the pathophysiology and downstream manifestations of sickle cell disease (SCD). Aims: This present study was carried out to determine MPs profiles in patients with SCD before and after transfusion and to compare these profiles with healthy subjects. Materials: Twenty healthy donors and twelve polytransfused patients with SCD recruited from National Bone Marrow Transplant Center were recruited in this study. None of the patients was transfused for at least 3 weeks before sampling. The blood samples obtained were analyzed for circulating MPs by flow cytometry. The cellular origin was determined by a multiple labeling with specific antibodies and dyes. Results: A high level of apoptotic, platelets, and endothelial MPs with the predominance of the number of erythrocyte MPs was detected in SCD patients compared to healthy donors. This suggests that erythrocytes MPs may contribute to thrombotic risk in sickle cell patients. Moreover, after transfusion most subjects register a decreased number of different types of MPs. Conclusion: Transfusion is an effective treatment option in patients with SCD, as it seems that it decreases the abnormally elevated levels of MPs.